Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
FDA Refuse-To-File Decisions Are Rare, But CMC And Ignoring Agency Advice Are Often Triggers
Feb 18 2021
•
By
Sarah Karlin-Smith
FDA analyzes 10 years of refuse-to-file letters in a new journal article • Source: Shutterstock
More from Approval Standards
More from Pathways & Standards